COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.


Update as of June 24th

XIFIN analyzed its vast stores of data, representative of four out of five top integrated delivery networks (IDNs) and seven out of the top ten independent laboratories nationwide, to craft the Lab Volume Index.

Currently, XIFIN sees 20-25% of all COVID-19 testing claims nationwide. The Lab Volume Index synthesizes billing volume data into a measurement of testing volumes as compared to a pre-coronavirus testing average (“baseline”).

Baseline volume is an average of weekly volumes represents current year pre-Coronavirus testing volumes. The Lab Volume Index measures billing volume data against a baseline volume, expressed as a percent of baseline.

This week we saw a dip in pain/tox COVID tests, which is due to to variances in submittal dates. In actuality, volume remains consistent and growing steadily for that segment, and we expect to see that reflected in our next numbers.